From Nasdaq: 2025-04-14 21:55:00

Bristol Myers Squibb’s Phase 3 ODYSSEY-HCM trial evaluating mavacamten for non-obstructive hypertrophic cardiomyopathy did not meet primary endpoints but no new safety signals were observed. Results contribute to understanding of nHCM.
Bristol Myers Squibb will share detailed results with scientific community in the future.



Read more at Nasdaq: Bristol Myers’ Heart Disease Drug Fails To Meet Primary Endpoints In Phase 3 Trial